Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | GRIA4 | P48058 | 12/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.34 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.33 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3703930 | 1.00 | CYP2C19 (0.47) | CYP2C19GRIA4CA1CA2KMT2A | |
| SCHEMBL6563345 | 0.92 | CYP2C19 (0.53) | CYP2C19GRIA4KMT2AEPHX2NR1H4 | |
| SCHEMBL13256290 | 0.88 | CYP2C19 (0.49) | CYP2C19GRIA4KMT2AGRIA1GRIA2 | |
| SCHEMBL13255837 | 0.88 | CYP2C19 (0.49) | CYP2C19GRIA4KMT2AGRIA1GRIA2 | |
| SCHEMBL5188496 | 0.86 | CYP2C19 (0.48) | CYP2C19GRIA4 | |
| SCHEMBL14394435 | 0.86 | CYP2C19 (0.48) | CYP2C19GRIA4CA1CA2KMT2A | |
| SCHEMBL5188470 | 0.85 | GRIA4 (0.48) | CYP2C19GRIA4CA1CA2KMT2A | |
| SCHEMBL5186070 | 0.82 | KMT2A (0.49) | CYP2C19GRIA4KMT2AEPHX2NR1H4 | |
| SCHEMBL4295879 | 0.82 | GRIA4 (0.46) | GRIA4CA1CA2GRIA1 | |
| SCHEMBL4295881 | 0.82 | GRIA4 (0.46) | GRIA4CA1CA2GRIA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010087982-A1 | GLUR2 RECEPTOR MODULATORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-08-05 | — | — | WO | disclosed |
| US-20090270508-A1 | GluR2 receptor modulators | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-10-29 | — | — | US | disclosed |
| EP-1183232-B1 | MONOFLUOROALKYL DERIVATIVES | LILLY CO ELI (US) | 2007-10-03 | — | — | EP | disclosed |
| EP-1183232-B1 | MONOFLUOROALKYL DERIVATIVES | LILLY CO ELI (US) | 2007-10-03 | — | — | EP | disclosed |
| US-7034045-B1 | Monofluoroalkyl derivatives | ELI LILLY AND COMPANY (US) | 2006-04-25 | — | — | US | disclosed |
| EP-1330233-B1 | METHOD OF TREATING STROKE | LILLY CO ELI (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040198833-A1 | Acetylenic sulfonamide derivatives | ELI LILLY AND COMPANY | 2004-10-07 | — | — | US | disclosed |
| US-20040063680-A1 | Method of treating stroke | CLEMENS JAMES ALLEN (US) | 2004-04-01 | — | — | US | disclosed |
| EP-1390072-A2 | USE OF AN AMPA RECEPTOR POTENTIATOR FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF TYPE 2 DIABETES | ELI LILLY AND COMPANY (US) | 2004-02-25 | — | — | EP | disclosed |
| US-20030220369-A1 | Heterocyclic sulfonamide derivatives and their use for potentiating glutamate receptor function | FORMAN SCOTT LOUIS (US) | 2003-11-27 | — | — | US | disclosed |
| US-20030092770-A1 | Combination therapy for treatment of depression | ELI LILLY AND COMPANY | 2003-05-15 | — | — | US | disclosed |
| EP-1292311-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DEPRESSION COMPRISING AN ANTIDEPRESSANT AND AN AMPA RECEPTOR POTENTIATOR | ELI LILLY AND COMPANY (US) | 2003-03-19 | — | — | EP | disclosed |
| WO-2002089848-A2 | USE OF AN AMPA RECEPTOR POTENTIATOR FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF TYPE 2 DIABETES | ELI LILLY AND COMPANY (US) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002032389-A1 | METHOD OF TREATING STROKE | ELI LILLY AND COMPANY (US) | 2002-04-25 | — | — | WO | disclosed |
| WO-2002018329-A1 | ACETYLENIC SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-03-07 | — | — | WO | disclosed |
| EP-1183232-A2 | MONOFLUOROALKYL DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-03-06 | — | — | EP | disclosed |
| WO-2002014275-A2 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AND THEIR USE FOR POTENTIATING GLUTAMATE RECEPTOR FUNCTION | ELI LILLY AND COMPANY (US) | 2002-02-21 | — | — | WO | disclosed |
| WO-2001089530-A2 | COMBINATION THERAPY FOR TREATMENT OF DEPRESSION COMPRISING AN ANTIDEPRESSANT AND AN AMPA RECEPTOR POTENTIATOR | ELI LILLY AND COMPANY (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001089510-A2 | USE OF AN AMPA RECEPTOR POTENTIATOR FOR THE TREATMENT OF OBESITY | ELI LILLY AND COMPANY (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2000066546-A2 | MONOFLUOROALKYL DERIVATIVES | ELI LILLY AND COMPANY (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198833-A1 | Acetylenic sulfonamide derivatives | GRIN2A, GRIN2B, GRIN1 | CYP2C19 2200/4885GRIA4 11/4885CA1 423/4885 |
| US-20030092770-A1 | Combination therapy for treatment of depression | GRM2, GRIK2, GRIN2A | CYP2C19 2448/4885GRIA4 18/4885CA1 748/4885 |
| US-20040063680-A1 | Method of treating stroke | ASAH2, PCSK7, PCSK9 | CYP2C19 1569/4885GRIA4 811/4885CA1 348/4885 |
| US-20090270508-A1 | GluR2 receptor modulators | GRM2, GRIK2, GRIN2A | CYP2C19 4612/4885GRIA4 16/4885CA1 1934/4885 |
| US-20030220369-A1 | Heterocyclic sulfonamide derivatives and their use for potentiating glutamate receptor function | GRIN2A, GRIN1, GRIN2B | CYP2C19 1067/4885GRIA4 14/4885CA1 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.